2026年全球治療性核子藥物市場報告

近年來，治療性核子醫學市場發展迅速。預計該市場將從2025年的21.9億美元成長到2026年的25.1億美元，複合年成長率（CAGR）為14.5%。過去幾年的成長主要歸因於癌症發生率上升、碘-131在甲狀腺疾病治療中的早期應用、標靶癌症治療方法的匱乏、核醫領域的擴張以及放射性藥物臨床接受度的提高。

預計未來幾年，治療性核醫市場將快速成長，到2030年將達到42.7億美元，複合年成長率（CAGR）為14.3%。預測期內的成長要素包括新型治療性同位素的研發、精準癌症治療方法的推廣、核醫基礎設施投資的增加、放射性配體療法臨床試驗的增多以及靶向核藥物監管核准的加快。預測期內的主要趨勢包括靶向放射性藥物療法的廣泛應用、鎦-177和α發射同位素的廣泛使用、癌症特異性核藥物應用的成長、核藥物聯合治療的推廣以及對安全劑量測定和監管合規性的日益重視。

預計未來幾年，癌症發生率的上升將推動治療性核藥市場的成長。癌症是一種以異常細胞不受控制地增生和擴散為特徵的疾病。癌症發生率的上升被認為與多種因素有關，例如檢測和診斷能力的提高、生活方式相關因素、環境暴露以及遺傳易感性。治療性核藥物在癌症治療中發揮著至關重要的作用，它們提供定向有效的治療方案，有助於減輕腫瘤負荷、緩解症狀並提高患者的生活品質。例如，根據聯合國機構世界衛生組織（世衛組織）2024年2月發布的預測，2050年，預計將有超過3,500萬例新增癌症病例，比2022年估計的2,000萬例增加77%。因此，癌症盛行率的上升正在推動治療性核藥物市場的成長。

在治療性核醫市場中，主要企業正透過新的臨床證據，強調多腫瘤治療的潛力，進而推動標靶放射治療解決方案的發展。這些努力旨在加強創新管線，拓展治療適應症，並加速下一代放射性藥物的應用。例如，總部位於美國的臨床階段生物製藥公司Actinium Pharmaceuticals於2025年公佈了其首個基於錒-225的放射治療藥物ATNM-400的最新臨床數據，該數據表明其對多種癌症類型（包括非小細胞肺癌（NSCLC））具有潛在療效。這些數據已在AACR-NCI-EORTC國際分子標靶與癌症治療大會上發表。 ATNM-400旨在提供高度標靶化、高效的α粒子治療，凸顯了其作為多種固體癌創新治療平台的潛力。這項進展表明，業界致力於拓展基於錒的放射放射線治療的臨床應用範圍，以改善患者預後並創造新的市場機會。

目錄

第1章執行摘要

第2章 市場特徵

• 市場定義和範圍
• 市場區隔
• 主要產品和服務概述
• 全球治療性核子藥物市場：吸引力評分及分析
• 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

• 供應鏈與生態系概述
• 清單：主要原料、資源和供應商
• 主要經銷商和通路合作夥伴名單
• 主要最終用戶列表

第4章：全球市場趨勢與策略

• 關鍵科技與未來趨勢
  • 生物技術、基因組學和精準醫療
  • 人工智慧（AI）和自主人工智慧
  • 工業4.0和智慧製造
  • 數位化、雲端運算、巨量資料、網路安全
  • 物聯網、智慧基礎設施、互聯生態系統
• 主要趨勢
  • 標靶放射性藥物治療的擴展
  • 擴大鎦-177和α發射同位素的使用
  • 癌症特異性核子藥物應用的發展
  • 利用核醫藥物進行聯合治療的擴展
  • 加強對安全性、劑量測量和法規遵循的關注。

第5章 終端用戶產業市場分析

• 醫院
• 癌症治療中心
• 門診手術中心（ASC）
• 癌症研究所
• 核子醫學診所

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

• 全球治療性核子藥物市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
• 全球治療性核子藥物市場規模、對比及成長率分析
• 全球治療性核能藥物市場表現：規模與成長，2020-2025年
• 全球治療性核能藥物市場預測：規模與成長，2025-2030年，2035年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

• 按類型
• 鐳-223、鎦-177、碘-131 及其他型
• 透過分銷管道
• 醫院、門診手術中心、癌症研究機構
• 透過使用
• 甲狀腺疾病、骨轉移、淋巴瘤及其他適應症

第10章 區域與國別分析

• 全球治療性核子藥物市場：按地區分類，實際結果和預測，2020-2025年、2025-2030年、2035年
• 全球治療性核子藥物市場：按國家/地區分類，實際數據和預測數據，2020-2025年、2025-2030年、2035年

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

• 治療性核能藥物市場：競爭格局與市場佔有率（2024 年）
• 治療性核能藥物市場：公司評估矩陣
• 治療性核能藥物市場：公司概況
  • Bayer AG
  • Novartis International AG
  • Siemens Healthineers AG
  • Ipsen SA
  • Jubilant DraxImage Inc.

第37章 其他大型企業和創新企業

• Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

第38章：全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

• 2030年治療性核子醫學市場：提供新機會的國家
• 2030年治療性核能藥物市場：充滿新機會的細分市場
• 2030年治療性核子藥物市場：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第41章附錄

Therapeutic nuclear drugs are a category of medications that use radioactive substances to treat diseases, especially cancer. These drugs employ targeted radiopharmaceuticals that attach to cancer cells and deliver therapeutic levels of radiation directly to them, helping destroy malignant cells while limiting damage to nearby healthy tissue.

The primary types of therapeutic nuclear drugs include radium-223, lutetium-177, iodine-131, and others. Radium-223 is a therapeutic nuclear drug mainly used for treating prostate cancer that has metastasized to the bones. These drugs are distributed through channels such as hospitals, ambulatory surgical centers, and cancer research institutes, and they are used for applications including thyroid disorders, bone metastasis, lymphoma, and others.

Tariffs have impacted the therapeutic nuclear drug market by increasing costs associated with imported radioactive isotopes, specialized manufacturing equipment, and shielding materials. Hospital-based nuclear medicine departments and cancer research institutes in regions such as North America and Europe are particularly affected due to dependence on cross-border isotope supply chains. These cost pressures can delay treatment availability and raise operational expenses. However, tariffs have also encouraged domestic isotope production, strengthened local supply chains, and stimulated investments in regional nuclear drug manufacturing capabilities.

The therapeutic nuclear drug market research report is one of a series of new reports from The Business Research Company that provides therapeutic nuclear drug market statistics, including therapeutic nuclear drug industry global market size, regional shares, competitors with a therapeutic nuclear drug market share, detailed therapeutic nuclear drug market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic nuclear drug industry. This therapeutic nuclear drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The therapeutic nuclear drug market size has grown rapidly in recent years. It will grow from $2.19 billion in 2025 to $2.51 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increasing cancer prevalence, early adoption of iodine-131 in thyroid disorders, limited availability of targeted oncology therapies, growth of nuclear medicine departments, rising clinical acceptance of radiopharmaceuticals.

The therapeutic nuclear drug market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to development of novel therapeutic isotopes, expansion of precision oncology approaches, increasing investment in nuclear medicine infrastructure, growing clinical trials for radioligand therapies, favorable regulatory approvals for targeted nuclear drugs. Major trends in the forecast period include rising adoption of targeted radiopharmaceutical therapies, increasing use of lutetium-177 and alpha-emitting isotopes, growth in cancer-specific nuclear drug applications, expansion of combination therapies with nuclear drugs, strengthening focus on safety dosimetry and regulatory compliance.

The rising prevalence of cancer is anticipated to drive the growth of the therapeutic nuclear drug market in the coming years. Cancer is a disease marked by the uncontrolled growth and spread of abnormal cells. The increasing occurrence of cancer is attributed to factors such as improved detection and diagnostic capabilities, lifestyle-related influences, environmental exposures, and genetic predispositions. Therapeutic nuclear drugs play a crucial role in cancer treatment by offering targeted and effective therapeutic options that help reduce tumor burden, relieve symptoms, and enhance patients' quality of life. For example, in February 2024, according to the World Health Organization, a Switzerland-based agency of the United Nations, it is projected that more than 35 million new cancer cases will be diagnosed by 2050, representing a 77% increase compared with the estimated 20 million cases recorded in 2022. As a result, the increasing prevalence of cancer is contributing to the growth of the therapeutic nuclear drug market.

Major companies operating in the therapeutic nuclear drug market are advancing targeted radiotherapy solutions by highlighting novel multi-tumor treatment potential through emerging clinical evidence. These initiatives are focused on strengthening innovation pipelines, broadening therapeutic indications, and accelerating the adoption of next-generation radiopharmaceuticals. For instance, in 2025, Actinium Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, released new clinical data for ATNM-400, its first-in-class Actinium-225-based radiotherapy, demonstrating potential efficacy across multiple tumor types, including non-small cell lung cancer (NSCLC). The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. ATNM-400 is engineered to deliver highly potent alpha-particle therapy with precise targeting, supporting its potential as a transformative treatment platform for a range of solid tumors. This development underscores the industry's emphasis on expanding the clinical scope of actinium-based radiotherapies to improve patient outcomes and unlock new market opportunities.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired QSAM Biosciences for an undisclosed amount. Through this acquisition, Telix Pharmaceuticals seeks to strengthen its therapeutic pipeline with the investigational drug Samarium-153-DOTMP, which is designed to target bone metastases and osteosarcoma. QSAM Biosciences is a US-based biotechnology company dedicated to the development of next-generation nuclear therapeutic medicines.

Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

North America was the largest region in the therapeutic nuclear drug market in 2025. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the therapeutic nuclear drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The therapeutic nuclear drug market consists of sales of yttrium-90, actinium-225, bismuth-213, therapeutic iodine-123, and copper-67. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Therapeutic Nuclear Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses therapeutic nuclear drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for therapeutic nuclear drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The therapeutic nuclear drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Radium-223; Lutetium-177; Iodine-131; Other Types
• 2) By Distribution Channel: Hospitals; Ambulatory Surgical Centers (ASCs); Cancer Research Institutes
• 3) By Application: Thyroid; Bone Metastasis; Lymphoma; Other Applications
• Companies Mentioned: Bayer AG; Novartis International AG; Siemens Healthineers AG; Ipsen S.A.; Jubilant DraxImage Inc.; Mallinckrodt Pharmaceuticals PLC; The Bracco Group; Lantheus Medical Imaging Inc.; Piramal Group; Curium Pharmaceuticals; Yantai Dongcheng Pharmaceutical Group Co. Ltd.; Eckert & Ziegler; Telix Pharmaceuticals Limited; International Isotopes inc.; Orano SA; Q BioMed Inc.; Molecular Targeting Technologies Inc; Medi-Radiopharma Co. Ltd.; Actinium Pharmaceuticals; Fusion Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Therapeutic Nuclear Drug Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Therapeutic Nuclear Drug Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Therapeutic Nuclear Drug Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Therapeutic Nuclear Drug Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Targeted Radiopharmaceutical Therapies
  • 4.2.2 Increasing Use Of Lutetium-177 And Alpha-Emitting Isotopes
  • 4.2.3 Growth In Cancer-Specific Nuclear Drug Applications
  • 4.2.4 Expansion Of Combination Therapies With Nuclear Drugs
  • 4.2.5 Strengthening Focus On Safety, Dosimetry, And Regulatory Compliance

5. Therapeutic Nuclear Drug Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Cancer Treatment Centers
• 5.3 Ambulatory Surgical Centers (Ascs)
• 5.4 Cancer Research Institutes
• 5.5 Nuclear Medicine Clinics

6. Therapeutic Nuclear Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Therapeutic Nuclear Drug Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Therapeutic Nuclear Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Therapeutic Nuclear Drug Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Therapeutic Nuclear Drug Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Therapeutic Nuclear Drug Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Therapeutic Nuclear Drug Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Therapeutic Nuclear Drug Market Segmentation

• 9.1. Global Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Radium-223, Lutetium-177, Iodine-131, Other Types
• 9.2. Global Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Research Institutes
• 9.3. Global Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Thyroid, Bone Metastasis, Lymphoma, Other Applications

10. Therapeutic Nuclear Drug Market Regional And Country Analysis

• 10.1. Global Therapeutic Nuclear Drug Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Therapeutic Nuclear Drug Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Therapeutic Nuclear Drug Market

• 11.1. Asia-Pacific Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Therapeutic Nuclear Drug Market

• 12.1. China Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Therapeutic Nuclear Drug Market

• 13.1. India Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Therapeutic Nuclear Drug Market

• 14.1. Japan Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Therapeutic Nuclear Drug Market

• 15.1. Australia Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Therapeutic Nuclear Drug Market

• 16.1. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Therapeutic Nuclear Drug Market

• 17.1. South Korea Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Therapeutic Nuclear Drug Market

• 18.1. Taiwan Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Therapeutic Nuclear Drug Market

• 19.1. South East Asia Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Therapeutic Nuclear Drug Market

• 20.1. Western Europe Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Therapeutic Nuclear Drug Market

• 21.1. UK Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Therapeutic Nuclear Drug Market

• 22.1. Germany Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Therapeutic Nuclear Drug Market

• 23.1. France Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Therapeutic Nuclear Drug Market

• 24.1. Italy Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Therapeutic Nuclear Drug Market

• 25.1. Spain Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Therapeutic Nuclear Drug Market

• 26.1. Eastern Europe Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Therapeutic Nuclear Drug Market

• 27.1. Russia Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Therapeutic Nuclear Drug Market

• 28.1. North America Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Therapeutic Nuclear Drug Market

• 29.1. USA Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Therapeutic Nuclear Drug Market

• 30.1. Canada Therapeutic Nuclear Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Therapeutic Nuclear Drug Market

• 31.1. South America Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Therapeutic Nuclear Drug Market

• 32.1. Brazil Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Therapeutic Nuclear Drug Market

• 33.1. Middle East Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Therapeutic Nuclear Drug Market

• 34.1. Africa Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Therapeutic Nuclear Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Therapeutic Nuclear Drug Market Regulatory and Investment Landscape

36. Therapeutic Nuclear Drug Market Competitive Landscape And Company Profiles

• 36.1. Therapeutic Nuclear Drug Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Therapeutic Nuclear Drug Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Therapeutic Nuclear Drug Market Company Profiles
  • 36.3.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Ipsen S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Jubilant DraxImage Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Therapeutic Nuclear Drug Market Other Major And Innovative Companies

• Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

38. Global Therapeutic Nuclear Drug Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Therapeutic Nuclear Drug Market

40. Therapeutic Nuclear Drug Market High Potential Countries, Segments and Strategies

• 40.1 Therapeutic Nuclear Drug Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Therapeutic Nuclear Drug Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Therapeutic Nuclear Drug Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer